Location Austin, Texas, United States Regions Southern US Gender Male
Mr. Allinson is Managing Director of the UT Horizon Fund, leading all aspects due diligence review and requirements for investment by UT System into UT startup companies. Capitalized by the UT System Board of Regents with $22.5 million, the UT Horizon Fund serves as the strategic venture fund to act as catalyst for commercialization. Focus is
placed on strategic thematic strengths of UT institutions including intellectual property, research strengths and innovative student ventures. Since starting the UT Horizon Fund in 2012, the UT Horizon Fund has made seven investments ranging from seed investments to late stage, from a broad class of industry sectors including pharmaceutical, medical device, nanotechnology, communications and web media.
Prior to founding the UT Horizon Fund, Mr. Allinson monetized royalty revenue in SOMAVERT®, a pharmaceutical product marketed by Pfizer, a deal valued at $52 million. He previously served as Director of Geisinger Ventures, a healthcare institutional venture firm, where he oversaw investments and joint ventures in the biotechnology, medical device, and healthcare information technology sectors. He previously served as a H. J. Heinz Technology Commercialization Fellow at Carnegie Mellon University and was part of the critical growth of several startup companies. One of Mr. Allinson’s patents is actively being used by the United States military in a class of products against chemical and biological warfare attacks. Bryan received an MBA from Carnegie Mellon University, and a dual bachelors degree in chemical engineering and chemistry from the University of Pittsburgh.
